Abstract
OBJECTIVE: The current study intends to find out the efficacy of Orlistat in the management of hyperlipidemia, Systolic Blood Pressure (SBP) and Body Mass Index (BMI).MATERIALS AND METHODS: This retro-spective study has evaluated the lipid profiles of the patients, who have been using metformin therapy for Type 2 diabetes. The study has ob-tained data regarding the parameters like tri-glyceride, Total cholesterol (TC), LDL cholester-ol, HDL cholesterol and LDL/HDL ratio, systol-ic blood pressure and Body Mass Index (BMI). Random distribution of patients was done into placebo and Orlistat groups. The placebo group received only metformin, and patients in the Or-listat group received Orlistat along with met-formin. After 24 weeks, the follow-up study was done, and statistical analysis was conducted.RESULTS: The study found that the Orlistat group has significant improvement (p<0.05) more improvement in LDL cholesterol, HDL cho-lesterol, Total cholesterol, LDL/HDL Ratio and Triglycerides, while BMI and systolic blood pres-sure did not show a significant difference be-tween placebo and Orlistat group.CONCLUSIONS: This study has concluded that Orlistat can be used for significant improve-ment in lipid profile. The study also found that Orlistat may not have a significant effect on re-ducing BMI and blood pressure without ade-quate lifestyle modification.